Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT05906706
Status
Approved For Marketing

Conditions

  • Bullous Pemphigoid

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • dupilumab — DRUG
    Subcutaneous (SC) administration

Study Details

The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.

Key Dates

Status verified
Jun 2025

Related Studies